Revelation Biosciences (NASDAQ:REVB) Issues Quarterly Earnings Results

Revelation Biosciences (NASDAQ:REVB) released its earnings results on Thursday. The company reported ($2.71) EPS for the quarter, missing the consensus estimate of ($1.15) by ($1.56), FiscalAI reports.

Revelation Biosciences Stock Performance

Shares of NASDAQ:REVB traded down $0.06 during midday trading on Friday, reaching $0.96. 224,262 shares of the company’s stock traded hands, compared to its average volume of 76,426. The company has a market cap of $3.57 million, a price-to-earnings ratio of -0.02 and a beta of -0.14. The stock has a 50 day moving average of $1.20 and a 200 day moving average of $2.60. Revelation Biosciences has a one year low of $0.95 and a one year high of $40.08.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Revelation Biosciences stock. Geode Capital Management LLC bought a new position in Revelation Biosciences, Inc. (NASDAQ:REVB) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 34,019 shares of the company’s stock, valued at approximately $27,000. Geode Capital Management LLC owned about 2.15% of Revelation Biosciences as of its most recent filing with the Securities and Exchange Commission (SEC). 12.80% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised Revelation Biosciences from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, April 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, Revelation Biosciences currently has a consensus rating of “Sell”.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.